Health

STAT+: Pharmalittle: We’re reading about Roche investments in Germany, a Gilead bowel disease drug, and more

Read full article at source ↗

Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 20/10/2026, 07:22:24 UTC.

Briefings

The U.S. FDA Center for Drug Evaluation and Research established a board to oversee exclusivity decisions for new chemical entities and clinical trial grants. This board aims to improve clarity and consistency in granting exclusivity to drugs with novel active ingredients or those relying on new clinical studies funded by drugmakers. Belgian Prime Minister Bart De Wever criticized U.S. and Chinese practices, arguing they threaten European pharmaceutical competitiveness and linked GSK restructuring to increased U.S. investment needs.

Key points

• The FDA Center for Drug Evaluation and Research formed a board to oversee exclusivity decisions for new chemical entities and clinical trial grants.
• De Wever criticized U.S. and Chinese practices, arguing they threaten European pharmaceutical competitiveness and linked GSK restructuring to increased U.S. investment needs.

Context

The article reports on the formation of a U.S. FDA board to oversee exclusivity decisions for new drugs. It also mentions Belgian Prime Minister Bart De Wever's criticism of U.S. and Chinese practices regarding pharmaceutical competitiveness and GSK restructuring.

Limitations

Evidence is limited to Reuters and Anadolu Agency reports. No specific dates, numbers, or names of drugmakers beyond GSK are provided. No causal claims are supported beyond reported statements.

Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 20/10/2026, 07:35:11 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.

View archived briefing on IPFS
bafybeifed7a77fgtjcrwmh7sntep72v4v6fr63fr5c4siq5dmvwnt5njwa